Merck (MRK) Q2 2026 Earnings: Revenue Beat Highlights Pipeline Progress Amid Acquisition Costs
Key Takeaways
- Revenue exceeded expectations: Merck posted second-quarter 2026 sales of $16.6 billion, up 5% year over year and ahead of the $16.41 billion consensus estimate.
- Non-GAAP EPS beat convincingly: The company reported an adjusted loss of $0.13 per share, significantly better than the $0.27 loss Wall Street had forecast.
- Terns acquisition drove the bottom-line loss: Both GAAP and non-GAAP results included a $2.31 per share charge tied to the $6.8 billion acquisition of Terns Pharmaceuticals.
- New product launches gained momentum: Recently launched drugs generated $1.5 billion in quarterly revenue, more than double the $0.6 billion from the same period last year.
- Full-year revenue guidance was raised: Merck lifted and narrowed its 2026 sales outlook to $66.3 billion–$67.3 billion, while lowering EPS guidance to reflect acquisition-related costs.
Putting Merck’s Results in Context
Merck’s second-quarter 2026 results, released on August 4, came at an important time for the pharmaceutical company. With its flagship cancer immunotherapy KEYTRUDA facing eventual patent expiration later this decade, Merck has been pursuing a strategy to build a more diversified set of growth drivers. This quarter provided a useful snapshot of how that effort is translating into actual sales. The numbers also reflected the impact of the company’s recent deal-making, particularly the $6.8 billion acquisition of Terns Pharmaceuticals, so investors could assess whether near-term costs are being offset by operational strength and pipeline advancement. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Numbers
Merck reported worldwide sales of $16.6 billion for the second quarter of 2026, a 5% increase from $15.8 billion in the prior-year period, or 4% excluding foreign exchange effects. The top line came in above the analyst consensus of $16.41 billion.
On the bottom line, Merck recorded a non-GAAP loss of $0.13 per share. Although a loss, this result was notably better than the consensus estimate of a $0.27 loss per share. The GAAP loss was $0.54 per share, compared with a profit of $1.76 per share in the second quarter of 2025. Both GAAP and non-GAAP figures included a $2.31 per share charge related to the Terns Pharmaceuticals acquisition.
The KEYTRUDA family, including the subcutaneous formulation KEYTRUDA QLEX, generated $8.4 billion in sales, up 4% on a constant-currency basis. WINREVAIR, the treatment for pulmonary arterial hypertension, saw sales rise 75% to $588 million. WELIREG climbed 67% to $271 million. GARDASIL vaccine sales reached $1.17 billion, up 4%. Animal Health contributed $1.78 billion, an 8% increase.
Revenue from recently launched products, including WINREVAIR, KEYTRUDA QLEX, CAPVAXIVE, OHTUVAYRE, ENFLONSIA, and others, totaled $1.5 billion, more than doubling from $0.6 billion a year earlier. Non-GAAP gross margin was 81.1%, down 1.1 percentage points, mainly due to higher inventory reserves.
Market Reaction and Investor Sentiment
Merck shares rose approximately 1.4% in pre-market trading following the earnings release on August 4, showing investor approval of the revenue beat and the performance of newer products. The stock, which closed the prior session at $127.77, traded near the upper end of its 52-week range of $77.58 to $135.05, reflecting broader market confidence in the diversification strategy.
The post-earnings move was relatively measured. The reduction in full-year EPS guidance—from $5.04–$5.16 to $2.66–$2.76—was anticipated and primarily reflects the Terns acquisition charge rather than any operational shortfall. Investors appeared to focus on the underlying sales trajectory, pipeline progress, and the raised revenue forecast.
Forward Outlook and Key Factors to Monitor
Looking ahead, Merck’s story will center on sustaining growth beyond KEYTRUDA. The company now guides for full-year 2026 revenue of $66.3 billion to $67.3 billion, implying 2% to 4% growth, and non-GAAP EPS of $2.66 to $2.76, a range that includes roughly $2.43 per share in total charges tied to the Terns deal.
Several potential catalysts are worth watching. The July FDA approval of LIPFENDRA (enlicitide), the first once-daily oral PCSK9 inhibitor for adults with hypercholesterolemia, opens a sizable cardiometabolic market. The Phase 3 readout for sac-TMT in advanced endometrial cancer met both overall survival and progression-free survival endpoints, marking the first positive pivotal data from the broad sac-TMT program that includes 17 ongoing Phase 3 trials.
In HIV, positive Phase 3 results were presented for the once-weekly oral regimen combining islatravir and lenacapavir (ISL/LEN), developed with Gilead. On the immunology side, tulisokibart met primary and key secondary endpoints in a Phase 3 ulcerative colitis induction study, though a separate trial in systemic sclerosis-associated interstitial lung disease was discontinued after missing its primary endpoint.
Operating expenses are now expected to reach $42.0 billion to $42.7 billion for the full year. Gross margin is projected around 81%. Investors should watch the pace of new product adoption, particularly LIPFENDRA’s early trajectory, along with further sac-TMT data and the competitive environment in oncology and vaccines.
Enhancing My Research with Tickeron Tools
In my regular analysis, I sometimes use Tickeron’s AI Screener to quickly filter for stocks with comparable earnings momentum or technical patterns. It helps surface relevant ideas more efficiently than manual screening alone, which complements the earnings review process without replacing traditional due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Aroon Indicator for MRK shows an upward move is likely
MRK's Aroon Indicator triggered a bullish signal on August 24, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 255 similar instances where the Aroon Indicator showed a similar pattern. In of the 255 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 12, 2026. You may want to consider a long position or call options on MRK as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MRK just turned positive on August 13, 2026. Looking at past instances where MRK's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in of 336 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MRK broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. MRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.865) is normal, around the industry mean (19.422). MRK's P/E Ratio (120.528) is considerably higher than the industry average of (33.317). Projected Growth (PEG Ratio) (10.337) is also within normal values, averaging (11.305). Dividend Yield (0.022) settles around the average of (0.027) among similar stocks. P/S Ratio (5.615) is also within normal values, averaging (4.270).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of human and animal health products
Industry PharmaceuticalsMajor
Advertisement